Vmax Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Net Worth -62.61%
- Total Assets -50.01%
About Vmax Therapeutics
Vmax Therapeutics Private Limited (VTPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 June 2018 (Six years and eight months 20 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Corporate was formerly known as Vicyclx Labs India Private Limited. The Company is engaged in the Research & Development Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mahesh Nanjundappa and Seegebagi Ashok serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U73100KA2018PTC113667
- Company No.
113667
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jun 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Vmax Therapeutics?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahesh Nanjundappa  | Director | 15-Apr-2022 | Current |
| Seegebagi Ashok | Director | 15-Apr-2022 | Current |
Financial Performance of Vmax Therapeutics.
Vmax Therapeutics Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth observed a substantial decline by a decrease of 62.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Vmax Therapeutics?
Unlock access to Vmax Therapeutics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Theraindx Lifesciences Private LimitedMahesh Nanjundappa is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Vmax Therapeutics?
Unlock and access historical data on people associated with Vmax Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vmax Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vmax Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
